THE EFFECTS OF MIRABEGRON AND TAMSULOSIN FOR PATIENTS WITH URETERAL STENTS
Status:
Completed
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
Double J stent (ureteral stent) can cause discomfort to patients, generally due to irritation
of the bladder mucosa, especially in the trigone area, smooth muscle spasm, and reflux of
urine into the ureter. Complaints often appear in patients, especially lower urinary tract
symptoms (LUTS), pain in the waist when urinating due to reflux of urine, sexual dysfunction,
and hematuria.
Currently, to assess complaints after ureteral stent placement, the Ureteral Stent Symptom
Questionnaire instrument consists of 6 topics: urinary complaints, pain, general health,
work, sexual problems, and other things.
Interleukin-6 is an important inflammatory cytokine when irritation occurs after ureteral
stent placement. Interleukin 10 is a cytokine with potent anti-inflammatory properties that
plays a central role in limiting the host's immune response to pathogens, thereby preventing
host damage and maintaining normal tissue homeostasis. The profile of these biomarkers has
the potential to determine the correct prognosis and therapy.
Mirabegron is a β3 adrenergic receptor agonist that has a dual antioxidant effect that plays
a key role in the first step of the antimicrobial response and early resolution of
inflammation so that post-stent complaints similar to overactive bladder complaints can be
resolved. Tamsulosin (a selective α1A- and α1D-adrenoceptor antagonist) has a relaxing effect
on the smooth muscle in the prostate, the neck of the bladder, and the distal ureter, thereby
reducing the inflammatory reaction and improving oxidative stress by reducing the formation
of reactive oxidative stress.